Details for New Drug Application (NDA): 202354
✉ Email this page to a colleague
NDA 202354 describes ETOMIDATE, which is a drug marketed by Avet Lifesciences, Caplin, Endo Operations, Eugia Pharma, Gland Pharma Ltd, Hikma, Luitpold, Mylan Labs Ltd, Rising, and Zydus Pharms, and is included in eleven NDAs. It is available from twelve suppliers. Additional details are available on the ETOMIDATE profile page.
The generic ingredient in ETOMIDATE is etomidate. There are six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the etomidate profile page.
The generic ingredient in ETOMIDATE is etomidate. There are six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the etomidate profile page.
Pharmacology for NDA: 202354
| Physiological Effect | General Anesthesia |
Medical Subject Heading (MeSH) Categories for 202354
Suppliers and Packaging for NDA: 202354
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ETOMIDATE | etomidate | INJECTABLE;INJECTION | 202354 | ANDA | Hikma Pharmaceuticals USA Inc. | 0143-9310 | 0143-9310-10 | 10 VIAL, SINGLE-DOSE in 1 CARTON (0143-9310-10) / 10 mL in 1 VIAL, SINGLE-DOSE (0143-9310-01) |
| ETOMIDATE | etomidate | INJECTABLE;INJECTION | 202354 | ANDA | Hikma Pharmaceuticals USA Inc. | 0143-9311 | 0143-9311-10 | 10 VIAL, SINGLE-DOSE in 1 CARTON (0143-9311-10) / 20 mL in 1 VIAL, SINGLE-DOSE (0143-9311-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 2MG/ML | ||||
| Approval Date: | Feb 25, 2016 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
